Crossmark

Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy

Crossref DOI link: https://doi.org/10.1007/s00018-022-04462-4

Published Online: 2022-07-16

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shi, Deyao https://orcid.org/0000-0003-4131-1027
Mu, Shidai

Pu, Feifei

Zhong, Binlong

Hu, Binwu

Muhtar, Muradil

Tong, Wei

Shao, Zengwu

Zhang, Zhicai

Liu, Jianxiang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82072978, 82072979)

Natural Science Foundation of Hubei Province (2020CFB861)
License Information

Text and Data Mining valid from 2022-07-16

Version of Record valid from 2022-07-16
More Information

Article History

Received: 9 April 2022

Revised: 16 June 2022

Accepted: 1 July 2022

First Online: 16 July 2022

Declarations

:

: The authors declare that they do not have any competing conflicts of interest.

: All authors reviewed and approved the final manuscript for publication.

: The patient cohorts we used were publicly available datasets that were collected with patients’ informed consent.

Document is current

Any future updates will be listed below